Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (Q30053056)
Jump to navigation
Jump to search
scientific article (publication date: November 2012)
Language | Label | Description | Also known as |
---|---|---|---|
English | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial |
scientific article (publication date: November 2012) |
Statements
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (English)
1 reference
Hans-Peter Hartung
1 reference
25 May 2017
Gavin Giovannoni
1 reference
25 May 2017
Howard L Weiner
1 reference
Jeffrey A Cohen
1 reference
Alasdair J Coles
1 reference
Douglas L Arnold
1 reference
Christian Confavreux
1 reference
Edward J Fox
1 reference
Eva Havrdova
1 reference
Krzysztof W Selmaj
1 reference
Elizabeth Fisher
1 reference
Vesna V Brinar
1 reference
Miroslav Stojanovic
1 reference
Bella I Ertik
1 reference
Stephen L Lake
1 reference
David H Margolin
1 reference
Michael A Panzara
1 reference
D Alastair S Compston
1 reference
November 2012
1 reference
1 reference
380
1 reference
9856
1 reference
1819-1828
1 reference